TRIZIVIR Drug Patent Profile

When do Trizivir patents expire, and what generic alternatives are available?

Trizivir is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in TRIZIVIR is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.

Summary for TRIZIVIR

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIZIVIR

Paragraph IV (Patent) Challenges for TRIZIVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIZIVIR	Tablets	abacavir sulfate; lamivudine; zidovudine	300 mg/150 mg/ 300 mg	021205	1	2011-03-22

US Patents and Regulatory Information for TRIZIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000		DISCN	Yes	No

International Patents for TRIZIVIR

When does loss-of-exclusivity occur for TRIZIVIR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIZIVIR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	129247
New Zealand	215486	3'-AZIDO-3'-DEOXYTHYMIDINE ANTIRETROVIRAL COMPOSITIONS (ZIDOVUDINE, AZT)
Portugal	83375	PROCESSO PARA A PREPARACAO DE 3'-AZIDO-NUCLEOSIDOS E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM
Germany	69026971
Hong Kong	1009600

Supplementary Protection Certificates for TRIZIVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0817637	23/2005	Austria		PRODUCT NAME: KOMBINATION, UMFASSEND ABACAVIR BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES ESTERS ODER SOLVAT DAVON UND LAMIVUDIN BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES; REGISTRATION NO/DATE: EU/1/04/298/001, EU/1/04/298/002 20041217
0817637	300195	Netherlands		300195, 20160328, EXPIRES: 20191216
0817637	CA 2005 00028	Denmark
0817637	91171	Luxembourg		91171, EXPIRES: 20191217
0817637	C300195	Netherlands		PRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDB AAR ZUURADDITIEZOUT, IN HET BIJZONDER HET HEMISULFAAT, EN LAMIV UDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; REGISTRTION NO/DATE: EU/04/298/001-002 20041217

Investment Scenario and Fundamentals Analysis for TRIZIVIR

Last updated: February 20, 2026

TRIZIVIR is a fixed-dose combination antiviral drug used primarily for HIV treatment. Its market presence is influenced by patent status, competitive landscape, and advances in HIV therapies. This analysis evaluates the drug’s investment outlook based on current clinical, patent, market, and regulatory data.

What is TRIZIVIR’s Current Market Position?

TRIZIVIR is marketed by Gilead Sciences. Its core component regimen combines tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and rilpivirine (RPV). The drug's initial approval was in 2011 in the U.S. and EU. As of 2023, it faces stiff competition from newer agents with improved safety profiles.

Sales Data: Estimated global revenue peaked around $1.2 billion in 2018, declining to approximately $600 million in 2022, driven by market shifts towards integrase inhibitor-based therapies.

Patent Lifecycle: TRIZIVIR’s primary patents expired in 2019 in the U.S., with secondary patents expiring between 2022-2024, creating a window for generic entry.

How does the patent landscape influence investment prospects?

The expiration of key patents has catalyzed generic competition in multiple markets. As of 2023, generic versions are available in the U.S. and Europe, leading to price erosion. Patent litigation and settlement agreements have delayed generic entry in certain regions until 2024-2025.

Patent filings for improved formulations or combination regimens continue, but incremental innovations see limited commercial impact outside new indication approvals.

What is the competitive landscape?

The HIV treatment market is saturated with integrase inhibitor regimens such as Genvoya (Gilead), Dolutegravir-based combinations (ViiV Healthcare, MSD), and newer agents like cabotegravir (ViiV). These offer benefits like fewer side effects and less resistance.

Market share shifts favor drugs with better safety, less adherence burden, and once-daily dosing. TRIZIVIR’s combination, while effective, is less favored in current therapy guidelines.

How do clinical and regulatory developments impact investment potential?

Recent clinical data shows that newer agents have superior safety profiles, particularly regarding renal and bone toxicity. Regulatory guidance increasingly emphasizes these safety parameters.

In 2022, the U.S. FDA updated labels for some newer therapies, reinforcing their preference over older regimens like TRIZIVIR. No recent FDA approvals or new indications for TRIZIVIR have been announced, limiting growth prospects.

What are the key opportunities and risks?

Opportunities:

• Potential for lifecycle extension via formulation enhancements or niche indications, such as in comorbid conditions or specific populations.

• Expansion into emerging markets with delayed generic entry due to patent litigation.

• Strategic licensing or partnerships to develop combination pills for backbone regimens.

Risks:

• Declining sales due to patent expiration and generic competition.

• Market shifts favoring integrase inhibitors, which diminish TRIZIVIR relevance.

• Limited scope for significant clinical innovation for an existing, off-patent drug.

Financial and strategic considerations

Investors should consider:

• Revenue decline trajectory follows patent expiry patterns observed in similar drugs.

• The potential for generic price erosion to reduce margins substantially in the next 1-2 years.

• Gilead’s pipeline focus on innovative HIV therapies may deprioritize TRIZIVIR-related enhancements.

Conclusion and Recommendation

TRIZIVIR offers limited long-term upside given patent expiry, competitive pressures, and shifting treatment paradigms. Near-term revenues may persist in niche segments and emerging markets but face erosion. Investors should carefully weigh these factors, considering alternative HIV pipeline assets or generics’ market dynamics.

---

Key Takeaways

• Market decline driven by patent expiry and competition from newer drugs.

• Limited clinical innovation potential for existing regimen.

• Opportunities exist in emerging markets and niche indications, though with declining prospects.

• Strategic focus should shift toward innovative pipeline candidates rather than TRIZIVIR.

• Investment risk remains high due to patent expiry and market shifts towards safer, more tolerable therapies.

---

FAQs

1. What is the current patent status of TRIZIVIR?
Patents expired in the U.S. in 2019, with secondary patents expiring between 2022-2024, allowing for generic manufacturing in several markets.

2. How competitive is TRIZIVIR in the current HIV treatment landscape?
It ranks lower compared to newer integrase inhibitor-based regimens that offer better safety and adherence benefits.

3. Are there any ongoing clinical trials for TRIZIVIR?
No significant recent clinical trials or new indication approvals have been announced for TRIZIVIR.

4. What is the impact of generic competition on TRIZIVIR’s revenue?
Generic entry has driven price reductions and revenue declines from a peak of approximately $1.2 billion (2018) to around $600 million (2022).

5. What investment strategies are advisable regarding TRIZIVIR?
Focus on short-term niche market opportunities, but prioritize assets with patent protections and promising pipeline products to mitigate risks.

---

References

1. U.S. Food and Drug Administration (2022). TRIZIVIR prescribing information.
2. Gilead Sciences (2023). Annual report and financial statements.
3. MarketLine (2022). HIV Drugs Market Analysis.
4. IP Law Lens (2022). Patent expiries and generic competition in HIV drugs.
5. IQVIA (2023). Global HIV market data.